Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $1.5 billion.

  • Haemonetics' Non-Current Assets rose 143.0% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.2 billion, marking a year-over-year increase of 116.35%. This contributed to the annual value of $1.5 billion for FY2025, which is 625.82% up from last year.
  • Per Haemonetics' latest filing, its Non-Current Assets stood at $1.5 billion for Q4 2025, which was up 143.0% from $1.5 billion recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' Non-Current Assets peaked at $1.6 billion during Q3 2024, and registered a low of $1.1 billion during Q1 2022.
  • Its 5-year average for Non-Current Assets is $1.3 billion, with a median of $1.2 billion in 2022.
  • As far as peak fluctuations go, Haemonetics' Non-Current Assets soared by 6977.03% in 2021, and later plummeted by 201.3% in 2022.
  • Quarter analysis of 5 years shows Haemonetics' Non-Current Assets stood at $1.1 billion in 2021, then rose by 6.31% to $1.2 billion in 2022, then increased by 22.5% to $1.4 billion in 2023, then grew by 6.27% to $1.5 billion in 2024, then grew by 1.43% to $1.5 billion in 2025.
  • Its Non-Current Assets stands at $1.5 billion for Q4 2025, versus $1.5 billion for Q3 2025 and $1.5 billion for Q2 2025.